Trial Profile
A Single-arm, Open-label and Exploratory Clinical Study of PD-1 Monoclonal Antibody SHR-1210 in Combination With GEMOX (Gemcitabine Combined Oxaliplatin) in Patients With Advanced Biliary Tract Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Oct 2021 Status changed from active, no longer recruiting to completed.
- 25 Jan 2020 Results, exploring predictive biomarkers analysis of expressions of PD-L1 and markers for lymphocyte, natural killer cells, and macrophages in baseline tumor tissue samples, presented at the 2020 Gastrointestinal Cancers Symposium
- 25 Jan 2020 Status changed from recruiting to active, no longer recruiting according to results presented at the 2020 Gastrointestinal Cancers Symposium.